Table 4.
Univariate and multivariate analyses of OS and PFS for 461 metastatic colorectal cancer patients.
| Parameter | Variable | OS univariate | Analysis | OS multivariate | Analysis | PFS univariate | Analysis | PFS multivariate | Analysis |
|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | ||
| Gender | Male versus female | 0.998 (0.773–1.287) | 0.985 | 1.026 (0.795–1.325) | 0.841 | ||||
| Age, years | <65 versus ≥65 | 1.310 (1.013–1.694) | 0.039 | 1.330 (0.998–1.772) | 0.052 | 1.067 (0.827–1.376) | 0.619 | ||
| Tumor location | Left/right colon versus rectum | 1.013 (0.884–1.162) | 0.849 | 1.089 (0.950–1.249) | 0.220 | ||||
| Primary tumor size, cm | <5 versus ≥5 | 1.077 (0.783–1.480) | 0.650 | 1.311 (0.955–1.800) | 0.094 | ||||
| Differentiation | Well/moderate versus poor | 1.031 (0.790–1.345) | 0.823 | 1.322 (1.016–1.721) | 0.038 | 0.395 (0.145–1.075) | 0.069 | ||
| Histological type | Papillary/tubular adenocarcinoma versus mucinous/signet ring cell | 1.142 (0.829–1.575) | 0.416 | 1.280 (0.929–1.764) | 0.131 | ||||
| Depth of invasion | T1 + T2 versus T3 + T4 | 0.952 (0.728–1.244) | 0.717 | 1.184 (0.912–1.536) | 0.205 | ||||
| Nodal stage | N0 + N1 versus N2a + N2b | 1.162 (0.980–1.378) | 0.084 | 1.245 (1.053–1.474) | 0.011 | 1.119 (0.920–1.361) | 0.260 | ||
| Metastatic site | Brain + lung versus liver + others | 1.540 (1.174–2.020) | 0.002 | 1.536 (1.130–2.088) | 0.006 | 1.728 (1.321–2.260) | <0.001 | 1.481 (1.094–2.006) | 0.011 |
| COX-2 expression | Negative versus positive | 1.046 (0.779–1.406) | 0.765 | 0.945 (0.704–1.270) | 0.709 | ||||
| Initial CEA (ng/mL) | <20 versus ≥20 | 3.103 (1.913–5.034) | <0.001 | 2.257 (1.366–3.730) | 0.001 | 2.659 (1.641–4.310) | <0.001 | 1.838 (1.113–3.036) | 0.017 |
| MSI | MSI-H versus MSI-L/MSS | 0.782 (0.493–1.238) | 0.294 | 0.688 (0.435–1.089) | 0.110 | ||||
| C-MET expression | Negative/weak versus moderate/strong | 1.690 (1.275–2.240) | <0.001 | 1.429 (1.052–1.940) | 0.022 | 1.495 (1.129–1.979) | 0.005 | 1.351 (0.993–1.839) | 0.055 |
| KRAS mutation | Yes versus no | 2.112 (1.620–2.754) | <0.001 | 1.826 (1.361–2.450) | <0.001 | 2.050 (1.574–2.671) | <0.001 | 2.082 (1.545–2.805) | <0.001 |
| BRAF mutation | Yes versus no | 8.615 (5.537–9.045) | <0.001 | 4.798 (2.989–7.700) | <0.001 | 4.458 (2.935–6.771) | <0.001 | 3.864 (2.375–6.287) | <0.001 |
| NRAS mutation | Yes versus no | 0.620 (0.230–1.668) | 0.344 | 0.462 (0.472–1.242) | 0.126 | ||||
| Anti-EGFR therapy | Yes versus no | 0.599 (0.401–0.894) | 0.012 | 0.742 (0.463–1.189) | 0.215 | 0.694 (0.465–1.036) | 0.074 | ||
| Bevacizumab therapy | Yes versus no | 0.713 (0.529–0.963) | 0.027 | 0.663 (0.469–0.937) | 0.020 | 0.758 (0.562–1.022) | 0.069 | 0.682 (0.484–0.961) | 0.029 |
| Surgery | Yes versus no | 0.702 (0.532–0.927) | 0.013 | 0.758 (0.531–1.082) | 0.127 | 0.712 (0.539–0.941) | 0.017 | 0.745 (0.525–1.057) | 0.099 |
OS = overall survival; PFS = progression-free survival; HR = hazard ratio; CI = confidence interval; COX-2 = cyclooxygenase-2; C-MET = mesenchymal-epithelial transition factor; CEA = carcinoembryonic antigen; MSI = microsatellite instability; MSI-H = MSI-high; MSI-L = MSI-low; MSS = microsatellite stability.